Evidence-based chemotherapeutic management of potentially platinum-sensitive recurrent ovarian cancer

ISSN： 1475-0708

Source： Therapy, Vol.7, Iss.3, 2010-05, pp. : 269-275

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 320-326

Karger

Access to resources Recommend Favorite

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-05 ,pp. : 433-437

Karger

Access to resources Recommend Favorite

Optimizing Management of Recurrent Epithelial Ovarian Cancer: A Critical Need for Evidence-Based Data

Oncology, Vol. 71, Iss. 5-6, 2007-09 ,pp. : 309-311

Karger

Access to resources Recommend Favorite

Haematological Evaluation of Weekly Therapy with Topotecan for the Treatment of Recurrent Ovarian Cancer Resistant to Platinum-Based Therapy

Oncology, Vol. 73, Iss. 3-4, 2008-04 ,pp. : 177-184

Karger

Access to resources Recommend Favorite

Evidence-based management?

By Kamill Paul

British Journal of General Practice, Vol. 54, Iss. 503, 2004-06 ,pp. : 467-467

Royal College of General Practitioners

Access to resources Recommend Favorite